Overview

* Phathom Q2 2025 revenue of $39.5 mln beats analyst expectations, per LSEG data

* Company reports 49% growth in VOQUEZNA prescriptions since last earnings report

* Phathom expects full-year 2025 revenue of $165 mln to $175 mln

Outlook

* Phathom expects 2025 revenue between $165 mln and $175 mln

* Company aims for profitability in 2026

* Phathom anticipates non-GAAP operating expenses under $60 mln in Q3 2025

* Company sees generic competition for VOQUEZNA unlikely before 2033

Result Drivers

* PRESCRIPTION GROWTH - 49% increase in VOQUEZNA prescriptions since last earnings report

* COMMERCIAL STRATEGY - Shifted focus to high-value prescribers, particularly gastroenterologists

* MARKET EXCLUSIVITY - Extended exclusivity for VOQUEZNA expected to support market position

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $39.50 $36.10

Revenue mln mln (8

Analysts

)

Q2 EPS -$1.05

Q2 Net -$75.81

Income mln

Q2 Basic -$1.05

EPS

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Phathom Pharmaceuticals Inc ( PHAT ) is $18.50, about 53.1% above its August 6 closing price of $8.68

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)